NCT05550961Recruiting
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Source: ClinicalTrials.gov · Last updated 23 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1200 (estimated)
- First submitted
- 19 Sept 2022
- Start date
- 1 Oct 2022
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Diseases
- Lung cancer
- NCT number
- NCT05550961
What you commit to
- Study type: Observational
- Planned participants: 1200
- From 1 Oct 2022 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.
- Patients who have not received an oncological systemic innovative therapy at any setting
- Patients received only local treatments (e.g., only surgery, or only radiotherapy)
- Patients who received only standard chemotherapy are excluded.
- Patients who received treatment therapies before 2010 are excluded.
Who the study is looking for
- Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;
- Patients must be ≥18 years of age at the time of signing the informed consent;
- Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS - Istituto Nazionale dei Tumori Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.